ENTITY
CSL Ltd

CSL Ltd (CSL AU)

111
Analysis
Health CareAustralia
CSL Limited develops, manufactures and markets human pharmaceutical and diagnostic products derived from human plasma. The Company's products include pediatric and adult vaccines, infection, pain medicine, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins.
more
Refresh
26 Sep 2018 18:37

Aussie Equities Model Portfolio Update

Good outperformance by staying long growth. Our model portfolio has a tilt towards Growth over Value and this has underpinned its solid...

Logo
414 Views
Share
bullishMSCI ACWI Index
07 Sep 2018 20:32

Bottoms-Up View on Developed Markets: Actionable Stocks, Part 2

Our outlook remains neutral for global ex-U.S. markets while horizontal consolidation continues on the MSCI ACWI ex-U.S. index.  In today’s report...

Logo
434 Views
Share
20 Aug 2018 20:22

Aussie Reporting Season Update: Cracks in the Mirror

Solid Earnings Momentum Hits a Brick Wall. It’s still early days, with only 40% of stocks reporting during the first 2 weeks of reporting season,...

Logo
361 Views
Share
bullishCSL Ltd
13 Jul 2018 10:57

Elevating Heart Rates as Potential CSL Blockbuster Enters Phase 3

A novel approach targeting recurrent heart attacks adds significant upside potential to CSL's pipelineBreakthrough medicine candidate CSL112...

Logo
447 Views
Share
bullishCSL Ltd
04 Apr 2018 07:51

Strong 1H18 Result and New Products Expected to Support Future Growth

CSL Ltd (CSL AU) reported their 1H18 result on 14 February 2018: Revenue $4,147m, up 11% at constant currency (cc) EBIT $1,476m, up 31% cc NPAT...

Share
x